000			nab a22 7a 4500
999			_c17028 _d17028
003			PC17028
005			20221024135251.0
008			221024b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_91463 _aMartín Ramos, María Luisa _eGenética
245	0	0	_aFluorescence in situ hybridization of TP53 for the detection of chromosome 17 abnormalities in myelodysplastic syndromes. _h[artículo]
260			_bLeukemia & lymphoma, _c2015
500			_aFormato Vancouver: Sánchez Castro J, Marco Betés V, Gómez Arbonés X, García Cerecedo T, López R, Talavera E et al; Spanish Group for Mds Study (GESMD); Spanish Group for Clinical Cytogenetics (Gcecgh). Fluorescence in situ hybridization of TP53 for the detection of chromosome 17 abnormalities in myelodysplastic syndromes. Leuk Lymphoma. 2015;56(11):3183-8.
501			_aPMID: 25754580
504			_aContiene 25 referencias
520			_aConventional G-banding cytogenetics (CC) detects chromosome 17 (chr17) abnormalities in 2% of patients with de novo myelodysplastic syndromes (MDS). We used CC and fluorescence in situ hybridization (FISH) (LSI p53/17p13.1) to assess deletion of 17p in 531 patients with de novo MDS from the Spanish Group of Hematological Cytogenetics. FISH detected - 17 or 17p abnormalities in 13 cases (2.6%) in whom no 17p abnormalities were revealed by CC: 0.9% of patients with a normal karyotype, 0% in non-informative cytogenetics, 50% of patients with a chr17 abnormality without loss of 17p and 4.7% of cases with an abnormal karyotype not involving chr17. Our results suggest that applying FISH of 17p13 to identify the number of copies of the TP53 gene could be beneficial in patients with a complex karyotype. We recommend using FISH of 17p13 in young patients with a normal karyotype or non-informative cytogenetics, and always in isolated del(17p).
710			_91466 _aServicio de Genética
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc17028.pdf _ySolicitar documento
942			_2ddc _cART _n0